Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma [Phase 3]
Phase 3 trial comparing romidepsin CHOP vs CHOP in untreated peripheral T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH [Phase 3]
Phase 3 trial comparing AC-CHOP to CHOP in previously untreated PTCL-TFH is currently enrolling by invitation.
-
CLINICAL_TRIALS trial_result · 2022-12-08Clinical Trial Update: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL [Phase 2]
Phase 2 trial results for pembrolizumab after autologous stem cell transplant in Hodgkin lymphoma, diffuse large B-cell lymphoma, and periph…
-
CLINICAL_TRIALS trial_result · 2022-11-09Clinical Trial Update: A Umbrella Study in R/R PTCL Guided by Molecular Subtypes [Phase 1, Phase 2]
An umbrella study in relapsed/refractory peripheral T cell lymphoma guided by molecular subtypes is described across Phase 1 and Phase 2 sta…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma [Phase 1, Phase 2]
Clinical trial update reports safety and efficacy results for Tenalisib (RP6530) in combination with Romidepsin in relapsed/refractory T-cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study evaluating mitoxantrone liposome with chidamide for relapsed/refractory peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-08-10Clinical Trial Update: A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 single-arm multicenter study evaluating mitoxantrone liposome in combination with chidamide and azacitidine for relapsed/refractor…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 study evaluating pembrolizumab (MK-3475) alone or with copanlisib in relapsed or refractory NK/T-cell non-Hodgkin lymphoma; the …
-
CLINICAL_TRIALS trial_result · 2022-07-01Clinical Trial Update: Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL [Phase 1, Phase 2]
An early-phase trial evaluating mitoxantrone hydrochloride liposomes in combination with GDP for relapsed/refractory peripheral T-cell lymph…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the combination of romidepsin and carfilzomib in relapsed/refractory peripheral T cell lymphoma has be…
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms [Phase 2]
Phase 2 study of BGB-A317 (tislelizumab) in adults with relapsed or refractory mature T- and NK-cell neoplasms has completed, with results p…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) [Phase 1]
Phase 1 trial evaluating subcutaneous recombinant human IL-15 in combination with alemtuzumab for refractory or relapsed adult T-cell leukem…
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy [Phase 2]
Phase 2 trial evaluating azacitidine combined with chidamide for newly diagnosed peripheral T-cell lymphoma patients unfit for conventional …
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients [Phase 2]
Phase 2 trial investigating brentuximab vedotin as a single agent for relapsed/refractory CD30+ peripheral T-cell lymphoma (PTCL).
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating parsaclisib in combination with CHOP for previously untreated peripheral T-cell lymphoma is ongoing, w…
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects [Phase 2]
Phase 2 clinical trial update evaluating Chi-BEAC with auto-HSCT for aggressive lymphomas, reporting on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients [Phase 3]
Phase 3 trial comparing pralatrexate to observation after CHOP-based chemotherapy in undiagnosed peripheral T-cell lymphoma patients; trial …
-
FDA approval · 2021-10-12FDA Approved: ROMIDEPSIN — Original Application (Fresenius Kabi USA, LLC)
FDA approved the original ANDA for romidepsin by Fresenius Kabi USA, LLC, providing a generic version of the cancer therapy for certain T-ce…
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma [Phase 2]
Phase 2 trial of belinostat in relapsed or refractory peripheral T-cell lymphoma has completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-09-10Clinical Trial Update: Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma [Phase 2]
Phase 2 trial evaluating nivolumab in combination with cabiralizumab for relapsed/refractory peripheral T cell lymphoma has completed with p…
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: Brentuximab Vedotin in Combination With CHEP in Patient With PTCL [Phase 2]
Phase 2 trial update evaluating Brentuximab Vedotin in combination with CHEP for peripheral T-cell lymphoma is in early stages with unknown …
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial of ABT-263 in relapsed or refractory lymphoid malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for E7777 in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma has completed rec…
-
CLINICAL_TRIALS trial_result · 2021-05-20Clinical Trial Update: CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for CC486-CHOP in patients with previously untreated peripheral T-cell lymphoma has completed with results pos…